<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52078">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054130</url>
  </required_header>
  <id_info>
    <org_study_id>CD-RI-MEDI9929-1146</org_study_id>
    <secondary_id>2013-003269-33</secondary_id>
    <nct_id>NCT02054130</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929
      (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe
      asthma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of asthma exacerbations</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Annualized asthma exacerbation rate (AER)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-bronchodilator FEV1 and FVC</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by pre-bronchodilator FEV1 and FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in post-bronchodilator FEV1 and FVC</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by post-bronchodilator FEV1 and FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in overall symptom score measured by the Asthma Daily Diary (ACQ-6)</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Asthma Daily Diary (ACQ-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe asthma exacerbations</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Annualized severe AER.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first asthma exacerbation/severe asthma exacerbation</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to first asthma exacerbation/severe asthma exacerbation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ[S] +12) and European Quality of Life (EQ-5D-5L)</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>AQLQ[S] +12 and EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numper of Participants with treatment-emergent adverse events and treatment-emergent serious adverse events</measure>
    <time_frame>Week 0 (Day 1) - Week 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Participants with treatment-emergent adverse events and treatment-emergent serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive antibodies to MEDI9929</measure>
    <time_frame>Week 0 (Day 1) - Week 64</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with positive antibodies to MEDI9929</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with one or more asthma exacerbations/severe asthma exacerbations</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of subjects with one or more asthma exacerbations/severe asthma exacerbations</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1383</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI9929 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI9929 (Investigational Product)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI9929 - Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI9929 (Investigational Product)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI9929 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI9929 (Investigational Product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Subcutaneous repeating dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI9929 - Low Dose IP</intervention_name>
    <description>Subcutaneous repeating dose</description>
    <arm_group_label>MEDI9929 - Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI9929 - Medium Dose IP</intervention_name>
    <description>Subcutaneous repeating dose</description>
    <arm_group_label>MEDI9929 - Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI9929 - High Dose IP</intervention_name>
    <description>Subcutaneous repeating dose</description>
    <arm_group_label>MEDI9929 - High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 75

          -  BMI between 18-40 kg/m2 and weight greater than or equal 40 kg

          -  Documented physician-diagnosed asthma  - Subjects must have received a
             physician-prescribed asthma controller regimen with medium- or high-dose ICS plus
             LABA -If on asthma controller medications in addition to ICS plus LABA, the dose of
             the other asthma controller medications (leukotriene receptor inhibitors,
             theophylline, secondary ICS, LAMA, cromones, or maintenance oral prednisone or
             equivalent up to a maximum of 10 mg daily or 20 mg every other day for the
             maintenance treatment of asthma) must be stable. -Subjects must have a documented
             history of at least 2 asthma exacerbation events.

        Exclusion Criteria:

          -  Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome,
             hyperventilation and panic attacks, or other mimics of asthma.

          -  Current smokers or subjects with a smoking history of ≥ 10 pack years

          -  Former smokers with &lt; 10 pack years must have stopped for at least 1 year to be
             eligible.

          -  Any concomitant respiratory disease that in the opinion of the investigator and/or
             medical monitor will interfere with the evaluation of the investigational product or
             interpretation of subject safety or study results (eg, chronic obstructive pulmonary
             disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic
             bronchopulmonary aspergillosis, Churg-Strauss syndrome).

          -  Evidence of active liver disease.

          -  History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix
             treated with apparent success with curative therapy or other malignancies are
             eligible provided that curative therapy was completed -Known history of active
             tuberculosis (TB)

          -  History of anaphylaxis to any biologic therapy

          -  Positive medical history for hepatitis B or C

          -  Subject with HIV or subject taking antiretroviral medications, as determined by
             medical history and/or subject's verbal report.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Parker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Mazza, MSHS, CCRA</last_name>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Crouch</last_name>
    <email>clinicaltrialenquiries@medimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herrico</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gödöllő</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
